|
HAYWARD, CA, February 7, 2000 - Sepragen Corporation (OTC BB:
SPGNU, SPGNA, SPGNW) today announced the appointment of Joseph R.
Mallon, Jr. to its Board of Directors.
Mr. Mallon is Chairman and CEO of Measurement Specialties, Inc. (AMEX:MSS).
Vinit Saxena, Chairman and
CEO of Sepragen Corporation stated “Joe Mallon’s operational success at
Measurement Specialties will be invaluable to Sepragen as we transition from the development of our
patented applications to maximizing the substantial commercial opportunities
for our products in the marketplace.”
Mr. Mallon became CEO of
Measurement Specialties in 1995 after serving as a member of its board. Under Mr. Mallon’s leadership, Measurement
Specialties’ revenues have tripled and earnings have increased ten fold. Mr. Mallon is a recognized pioneer in the
area of silicon micromaching and has been awarded 40 U.S. patents and has
published more than 50 papers.
“I am pleased to be joining
the board of Sepragen Corporation.” said Mr. Mallon, he added, “Sepragen is
poised with the technology and people to move from an extended entrepreneurial
phase to significant growth.As a
shareholder and Board member, I am excited with the prospect of working with
management to help in this time of exciting potential growth.”
Sepragen Corporation develops and markets technology along with equipment and supplies
for process chromatography applications. Sepragen has developed a number of patented
applications that provide large market opportunities in the food and beverage industry,
including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as
well as extracting proteins from whey. The company holds over 14 issued patents relating
to its core technology.
<
Back
The statements in this release that relate to future events
or performance, statements about growth, future regulatory clearances, levels of sales and
market size and future manufacturing capacity and efficiencies are forward-looking
statements that involve risks and uncertainties, including risks associated with
uncertainties related to the development of markets for and commercial acceptance of the
company's products and services, the availability of components, competitors' product
introductions and other risks identified in the company's SEC filings. Actual results may
differ from those described in these forward-looking statements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the
date hereof.
|
